20 -2 (52) 2023 — Abdurakhmanov M.M., Khasanova N.M. — MECHANISMS OF THE DEVELOPMENT OF CARDIOTOXICITY IN BREAST CANCER CHEMIRTERAPY

MECHANISMS OF THE DEVELOPMENT OF CARDIOTOXICITY IN BREAST CANCER CHEMIRTERAPY

Abdurakhmanov M.M., Bukhara State Medical Institute

Khasanova N.M., Bukhara State Medical Institute

Juraeva N.O. Bukhara State Medical Institute

Resume

Modern treatment of breast cancer is associated with risks of cardiotoxicity. The article presents the mechanisms of cardiotoxicity development on the example of drugs used in the treatment of breast cancer (anthracyclines and a targeted drug – trastuzumab). Diagnostic methods, their advantages and disadvantages, the algorithm of diagnosis and continuation of therapy of patients receiving cardiotoxic therapy of breast cancer are presented.

Keywords: chemotherapy, targeted therapy, cardiotoxicity, echocardiography, doxorubicin, trastuzumab, cardiomyopathy, cardiovascular complications.

First page

112

Last page

116

For citation: Abdurakhmanov M.M., Khasanova N.M., Juraeva N.O. – MECHANISMS OF THE DEVELOPMENT OF CARDIOTOXICITY IN BREAST CANCER CHEMIRTERAPY //New Day in Medicine 2(52)2023 112-116 https://clck.ru/33Y8de

LIST OF REFERENCES:

1. Беляева Н.Н., с соавт., Иммунорегуляторные клетки как потенциальные биомаркеры рака. Вестник Казанского НМУ ― 2016. ― №3. С. 185-191.
2. Селиверстова Д.В., Евсина О.В. Кардиотоксичность химиотерапии // Сердце: журнал для практикующих врачей. ― 2016. ― Т. 5, №1. ― С. 50-57.
3. Чазова И.Е., Ощепкова Е.В., Кириллова М.Ю., и др. Риск развития артериальной гипертонии у пациентов с онкологическими заболеваниями на фоне противоопухолевого лечения // Consilium Medicum. ― 2016. ― Т. 18, №1. ― С. 16-20.
4. Чазова И.Е., Ощепкова Е.В., Кириллова М.Ю., и др. Сердечно-сосудистые и онкологические заболевания: поиск решений новых проблем // Системные гипертензии. ― 2015. ― Т. 12, №2. ― С. 6-7.
5. Ewer M., Ewer S. Cardiotoxicity of anticancer treatments // Nat. Rev. Cardiol. ― 2015. ― Vol. 12. ― P. 547-558.
6. Armstrong G.T., Oeffinger K.C., Chen Y., et al. Modifiable risk factors and major cardiac events among adult survivors of childhood cancer // J. Clin. Oncol. ― 2013. ― Vol. 31, №29. ― P. 3673-3680.
7. Priorities in the Cardiovascular Care of Breast Cancer Survivors, Bonnie Ky, Show More // J. of Oncology Practice. ― 2018. ― Vol. 14, №4. ― P. 205-211.
8. Khouri M.G., Douglas P.S., Mackey J.R., et al. Cancer therapy-induced cardiac toxicity in early breast cancer: addressing the unresolved issues // Circulation. ― 2012. ― Vol. 126, №23. ― P. 2749-2763.
9. Maria Florescu et al. Chemotherapy-induced Cardiotoxicity // J. Clin. Medic. ― 2013. ― Vol. 8, №1. ― P. 59-67.
10. Billingham M.E., Mason J.W., Bristow M.R., Daniels J.R. Anthracycline cardiomyopathy monitored by morphologic changes // Cancer Treat Rep. ― 1978. ― Vol. 62, №6. ― P. 865-872.
11. Mackay B., Ewer M.S., Carrasco C.H., Benjamin R.S. Assessment of anthracycline cardiomyopathy by endomyocardial biopsy // Ultrastruct Pathol. ― 1994. ― Vol. 18, №1-2. ― P. 203-211.
12. Elzbieta Sadurska. Current Views on Anthracycline Cardiotoxicity in Childhood Cancer Survivors // Pediatr Cardiol. ― 2015. ― Vol. 36. ― P. 1112-1119.
13. Maria Florescu et al. Chemotherapy-induced Cardiotoxicity // J. Clin. Medic. ― 2013. ― Vol. 8, №1. ― P. 59-67.
14. Cardinale D., Colombo A., Lamantia G., et al. Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy // J. Am. Coll Cardiol. ― 2010. ― Vol. 55. ― P. 213-220.
15. de Azambuja E., Procter M.J., van Veldhuisen D.J., et al. Trastuzumab-associated cardiac events at 8 years of median follow-up in the Herceptin Adjuvant trial (BIG 1-01) // J. Clin. Oncol. ― 2014. ― Vol. 32. ― P. 2159-2165.
16. Suter T.M., Procter M., van Veldhuisen D.J., et al. Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial // J. Clin. Onco. ― 2007. ― Vol. 25. ― P. 3859-3865.
17. Zamorano J.L., Lancellotti P., Rodriguez Muñoz D., et al.: 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for Cancer Treatments and Cardiovascular Toxicity of the European Society of Cardiology (ESC) // Eur. Heart J. ― 2016. ― Vol. 37. ― P. 2768-2801.
18. Armenian S.H., Lacchetti C., Barac A., et al. Prevention and Monitoring of Cаrdiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline // J. Clin. Oncol. ― 2017. ― Vol. 35. ― P. 893-911.
19. Yeh E.T., Bickford C.L. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management // J. Am. Coll Cardiol. ― 2009. ― Vol. 53. ― P. 2231-2247. 
20. Daher I.N., Kim C., Saleh R.R. et al. Prevalence of abnormal echocardiographic findings in cancer patients: a retrospective evaluation of echocardiography for identifying cardiac abnormalities in cancer patients // Echocardiography. ― 2011. ―Vol. 28. ― P. 1061-1067.